Text Size

Safety and Efficacy Study of Lithium in Bipolar Disorder

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2007 by JDS Pharmaceuticals.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
JDS Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00422331
First received: January 11, 2007
Last updated: August 13, 2007
Last verified: August 2007
History of Changes
  Purpose

The purpose of this study is to determine whether Lithium is safe and effective in the treatment of Bipolar I Disorder subjects with symptoms of acute mania.


Condition Intervention Phase
Bipolar Disorder
Mania
 Drug: Lithium Carbonate Capsule
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Study of Lithium in Bipolar I Disorder

Resource links provided by NLM:

MedlinePlus related topics: Bipolar Disorder
U.S. FDA Resources

Further study details as provided by JDS Pharmaceuticals:

Primary Outcome Measures:
  • change from baseline in YMRS score

Secondary Outcome Measures:
  • change from baseline in CGI-BP score
  • change from baseline in MADRS score

Estimated Enrollment: 206
Study Start Date: January 2007
Estimated Study Completion Date: December 2007
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of Bipolar 1 Disorder;
  • Hospitalized or in the process of being hospitalized for a manic or mixed episode

Exclusion Criteria:

  • History of rapid cycling;
  • History of hypersensitivity or adverse reaction to lithium
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00422331

Locations
United States, New York
JDS Pharmaceuticals
New York, New York, United States, 10174
Sponsors and Collaborators
JDS Pharmaceuticals
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00422331     History of Changes
Other Study ID Numbers: JDS04004, Lithium TEAM-1 Study
Study First Received: January 11, 2007
Last Updated: August 13, 2007
Health Authority: United States: Food and Drug Administration
India: Ministry of Health

Keywords provided by JDS Pharmaceuticals:
Bipolar I Disorder
Bipolar Disorder
Lithium

Additional relevant MeSH terms:
Bipolar Disorder
Affective Disorders, Psychotic
Mood Disorders
Mental Disorders
Lithium
Lithium Carbonate
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
 Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs
Antimanic Agents
Antidepressive Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on May 19, 2013